RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @Dr_RaviMadan: @SbrtSean @EAntonarakis The data gets very flimsy if you go above 3 psma+ Mets. Best data is just psa progression benef…
@SbrtSean @EAntonarakis The data gets very flimsy if you go above 3 psma+ Mets. Best data is just psa progression benefit based on this analysis of 116 pts which is our best data in #prostatecancer we need more data. https://t.co/CIAR048sJW
@ChadTangMD @ndesai2005 @_ShankarSiva @OncoAlert @piet_ost @gu_onc @AzadOncology @ZilliThomas @JeffBradleyMD @MDAndersonNews @ASTRO_org @a_dalpra @whallradonc @DrSpratticus Agree that the radiographic growth is THE key measure. That is what I liked so much
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. https://t.co/U8dRQJO4p4
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
RT @JCO_ASCO: 🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observatio…
🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic #ProstateCancer 🎯 Largest benefit for patients harboring a high-risk mutation #PCSM @matthewdeek @piet_ost
Great collaboration between nuclear medicine @CalaisJeremie @CzerninJohannes and radiation oncology, supported by @PointBiopharma . We have learned from @piet_ost, Phuoc Tran and their teams that MDT alone may be insufficient for many of these men https://
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
#metastasis directed therapy in #ProstateCancer update by @matthewdeek and colleagues https://t.co/TRyV1WibM7
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials | Journal of Clinical Oncology https://t.co/SQetfAKlTv
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
🔥 Check out what’s hot this week in #JCO: Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic #ProstateCancer: Analysis of STOMP and ORIOLE Trials ➡️ https://t.co/dJ03VoUth2 #PCSM http
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials https://t.co/nTeOC7Tmtn ¿Que piensas de esto Tomas Merino? @merino_tomas
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
RT @piet_ost: Correct link: https://t.co/7bEFItCHOv
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
RT @RU_RadOnc: Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate…
Congratulations Dr. Deek @matthewdeek @RU_RadOnc @RutgersCancer @RWJMS for his study on oligometastatic disease in prostate cancer published @JCO_ASCO https://t.co/LCmFq6fPat https://t.co/RTq2WF49bq
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @piet_ost: Correct link: https://t.co/7bEFItCHOv
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @alongi_filippo: long-term outcomes of STOMP and ORIOLE demonstrate sustained benefit to MDT over observation in omCSPC.Genomic alterati…
RT @alongi_filippo: long-term outcomes of STOMP and ORIOLE demonstrate sustained benefit to MDT over observation in omCSPC.Genomic alterati…
RT @matthewdeek: Enjoyed working with @piet_ost @kim_vdeecken and Phu Tran on this. Hopefully we can continue to better understand the biol…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @matthewdeek: Enjoyed working with @piet_ost @kim_vdeecken and Phu Tran on this. Hopefully we can continue to better understand the biol…
RT @alongi_filippo: long-term outcomes of STOMP and ORIOLE demonstrate sustained benefit to MDT over observation in omCSPC.Genomic alterati…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @piet_ost: Correct link: https://t.co/7bEFItCHOv
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
Important work advancing genetics as a predictive and prognostic influencer for men with oligometastatic prostate cancer.
Enjoyed working with @piet_ost @kim_vdeecken and Phu Tran on this. Hopefully we can continue to better understand the biology of oligometastasis to personalize treatment. @RutgersCancer
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @alongi_filippo: long-term outcomes of STOMP and ORIOLE demonstrate sustained benefit to MDT over observation in omCSPC.Genomic alterati…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @piet_ost: Finally here: 1/ long term outcomes of the 2 RCT on #oligometastatic #prostatecancer (STOMP and ORIOLE). 2/Analysis of the im…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…
RT @alongi_filippo: long-term outcomes of STOMP and ORIOLE demonstrate sustained benefit to MDT over observation in omCSPC.Genomic alterati…
RT @_ShankarSiva: STOMP and ORIOLE long term outcomes. Metastasis-directed SABR in oligometastatic #prostatecancer ⬆️PFS from 5.9mo to 11.9…